CE Mark for DeepPath- LYDIA
We are super excited to announce that DeepPath receives CE marking for DeepPath- LYDIA. The system got regulatory clearance as decision support as per IVDD for helping histopathologists detect metastases on Hematoxylin & Eosin stained lymph nodes from patients with breast cancer, colon cancer, lung cancer, and melanoma. We must note that to the best [...]